GI Innovation and IDvine Join Hands for AI Drug Development

GI Innovation announced on the 24th that it has signed a memorandum of understanding (MOU) for AI collaboration with IDvine, an artificial intelligence (AI) performance prediction solution company, to differentiate new drug development. The MOU signing ceremony, held the previous day at GI Innovation's headquarters in Songpa-gu, Seoul, was attended by GI Innovation's Chairman Byung-gun Lee, Chief Strategy Officer (CSO) Myung-ho Jang, CEO Junho Hong, Executive Director Nari Yoon, and IDvine CEO Song-mi Kim.

At the AI collaboration MOU signing ceremony between GI Innovation and ID Vine held on the 23rd, attendees are taking a commemorative photo. Jang Myung-ho, Chief Strategy Officer (CSO) of GI Innovation; Lee Byung-geon, Chairman of GI Innovation; Kim Song-mi, CEO of ID Vine; Hong Jun-ho, CEO of GI Innovation; Yoon Na-ri, Executive Director of GI Innovation
[Photo by GI Innovation]

Through this agreement, the two companies plan to focus on establishing optimal clinical development strategies and discovering new targets for GI Innovation's core oncology pipelines GI-102 and GI-108 by utilizing IDvine's AI technology. Recently, global pharmaceutical companies have been competitively engaging in new drug development using AI by acquiring or collaborating with AI companies. As a result, it is evaluated that pharmaceutical companies alone, even with their concentrated expertise in the pharmaceutical field, find it difficult to keep pace with the rapid advancement of AI.

IDvine possesses proprietary AI models and bio-specialized large language models (LLMs) that analyze over one billion patents, papers, and bio data worldwide in real time, enabling highly accurate predictions of commercialization success potential. Based on this, it is explained that they can select new drug substances with a high likelihood of clinical trial success and establish strategies accordingly. In other words, they have technology that minimizes the possibility of failure by utilizing AI. Previously, IDvine analyzed the clinical success potential of over 16,000 new drug substances worldwide and released research results stating that "GI Innovation's GI-101A and GI-102 have the highest likelihood of success in Phase 1 and 2 clinical trials."

Byung-gun Lee, Chairman of GI Innovation, said, “AI-driven new drug development is rapidly growing, with the global market size estimated at 28 trillion won by 2030, and it is a key area where long-term government R&D projects over five years are being promoted. To stay ahead of the rapidly changing new drug development market trends, we expect synergy by collaborating with IDvine on AI and will focus on building new pipelines through the development of new modalities.”

Song-mi Kim, CEO of IDvine, also stated, “Through the convergence of AI and bio technologies, we can bring innovative changes to new drug development. This collaboration will play an important role in increasing the success rate of new drug development and provide new treatment options to more patients.”